Novo Nordisk Plans Value-based Contracts For GLP-1 Agonist Ozempic

 
• By Emily Hayes

Company aims to shift gradually away from once-daily GLP-1 Victoza (liraglutide) toward once-weekly Ozempic (semaglutide).

FDA approved background, 3D rendering, blue street sign

More from New Products

More from Scrip